Nifty Pharma Shares Slump 3% as Trump Hints Tariff on Drugmakers 

The Nifty Pharma index fell 3.5% on Thursday, April 2, following a significant selloff in frontline stocks. Sun Pharmaceutical Industries’ stock slumped 6% following reports that the Trump administration may slap tariffs on drugmakers. Other pharmaceutical stocks also fell in tandem with India’s largest drugmaker.

The Trump administration intends to impose tariffs on pharmaceutical companies that have not signed agreements to secure reduced medicine pricing in the United States.

Several major pharmaceutical corporations have already reached arrangements with the United States government.

Pfizer received a three-year tariff moratorium in September 2025, while AstraZeneca signed a Most Favored Nation pricing deal in October. In December, Roche agreed to decrease pricing in exchange for a three-year waiver.

Other businesses that have entered into such arrangements include Novartis, Eli Lilly, Johnson & Johnson, Merck, Novo Nordisk, and GSK.

Analysts claim that the proposed levies do not target generic medication makers. However, given its considerably higher exposure to branded medications, Sun Pharma may need to consider incremental steps such as pricing agreements, manufacturing expansions in the United States, or participation in the TrumpRx.gov platform.

Sun Pharma has the most exposure to branded medications among Indian peers. In FY25, the company’s US sales increased by 5.8% to Rs 16,200 crore, accounting for 31% of consolidated revenue. This development was attributed to the company’s growing specialist portfolio.

The future of investing is here!
Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!

The post Nifty Pharma Shares Slump 3% as Trump Hints Tariff on Drugmakers  appeared first on Equitypandit.